Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 2/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.45 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513268 | 0.88 | SLC16A3 (0.42) | SLC16A3SLC16A1MCTS1LMNASMN1; SMN2 | |
| SCHEMBL513313 | 0.80 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2MEN1ESR1KMT2A | |
| SCHEMBL29915428 | 0.77 | SLC16A3 (0.48) | SLC16A3SLC16A1MCTS1MAPTCA1 | |
| SCHEMBL513238 | 0.77 | SMN1; SMN2 (0.41) | SLC16A3SLC16A1MCTS1LMNASMN1; SMN2 | |
| SCHEMBL20600270 | 0.75 | MAPK14 (0.47) | SLC16A3SLC16A1MCTS1SMN1; SMN2MEN1 | |
| SCHEMBL22412857 | 0.75 | MAPT (0.50) | LMNASMN1; SMN2RAB9AALDH1A1GAA | |
| SCHEMBL27946642 | 0.75 | PDE5A (0.43) | LMNASMN1; SMN2MEN1ESR1KMT2A | |
| SCHEMBL22613701 | 0.74 | SLC16A3 (0.48) | SLC16A3SLC16A1MCTS1LMNASMN1; SMN2 | |
| SCHEMBL22613635 | 0.74 | SLC16A3 (0.48) | SLC16A3SLC16A1MCTS1NPC1RAB9A | |
| SCHEMBL24038948 | 0.72 | MAPT (0.56) | LMNASMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | SLC16A3 685/4885SLC16A1 753/4885MCTS1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.